Erratum


Byron C. Yoburn*, Vishal Purohit, Kaushal Patel, Qiuyu Zhang

Department of Pharmaceutical Sciences, College of Pharmacy and Allied Health Professions, St. John's University, 8000 Utopia Parkway, Queens, NY 11439, USA

Available online 11 November 2004

The Publisher herewith apologizes for the erroneous omission of the delta (δ) symbol in the above mentioned article in the following places:

Page 89, Section 2.4.1, 3rd paragraph:

“In addition, GH3 cells expressing the μ-opioid receptor or the δ-opioid receptor were analyzed using the Western blot protocol. There were no specific bands in samples from GH3 cells expressing δ-opioid receptors, whereas a single broad band was observed for samples from GH3 cells expressing μ-opioid receptors.”

Page 93, Section 4 Discussion, 3rd paragraph:

“This explanation would account for the increase in [3H] DAMGO binding with no change in immunoreactive μOR and agrees with recent studies that propose that opioid antagonists can act as pharmacological chaperones for δ-opioid receptors expressed in HEK 293 cells (Petaja-Repo et al., 2002). These authors propose that pharmacological chaperones such as naltrexone will accelerate maturation of δ-opioid receptors and cell surface targeting.”